Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Analyst Coverage: Thera "Speculative Buy"

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Dec 23, 2020 4:32pm

128 Views

Post# 32171885

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Analyst Coverage: Thera "Speculative Buy"

I agree with you and that is why I specifically said Egrifta for lipo. I really do not think the high price has played a big role in either drugs sales shortcomings. In the US, as long as the drug is reimbursed, doctors should only be concerned about its efficacy for their patient. Undoubtedly some doctors are influenced by the price, but technically, they should not be.

jfm1330 wrote: Come on SPCEO1! One of the two "unimpressive" drugs is the one they plan to go in phase III in NASH with and that you are very high on. It's not the drugs that are unimpressive, it's the markets for their approved indications. Add to that the very high prices of both drugs as part of the market penetration problem. Same old story.

SPCEO1 wrote:

I half want Paul to come out and say "Our current two drugs are really not that impressive and the outlook for sales of both are limited".